Sign in

CIK 0001880438

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
820606654
Phone
+1 650-331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
Open-market buys, last 90 days
$11,602
in 1 filing
Open-market sales, last 90 days
$117,428
in 4 filings, $104K under 10b5-1 plans

Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2022-06-06 Aziz Kabeer Director Other acquisition +26,511 $15.00 $398K 413,156
2022-06-06 Adjuvant Global Health Technology Fund, L.P. 10% owner Other disposition −26,511 $15.00 $398K 2,184,224
2022-06-06 Adjuvant Global Health Technology Fund, L.P. 10% owner Other acquisition +26,511 $15.00 $398K 413,156
2022-05-12 Chanda Sanjay Chief Development Officer Grant or award · Stock Option (right to buy) +66,000 66,000
2022-05-12 Readnour Robin Shane Director Grant or award · Stock Option (right to buy) +20,724 20,724
2022-05-12 Eckburg Paul Chief Medical Officer Grant or award · Stock Option (right to buy) +66,000 66,000
2022-05-12 Martin Patricia A. Director Grant or award · Stock Option (right to buy) +10,362 10,362
2022-05-12 Wong Stephanie Director Grant or award · Stock Option (right to buy) +10,362 10,362
2022-05-12 Nazak Michael Adrian Chief Accounting Officer Grant or award · Stock Option (right to buy) +14,300 14,300
2022-05-12 FitzPatrick Margaret M Director Grant or award · Stock Option (right to buy) +10,362 10,362
2022-05-12 Aziz Kabeer Director Grant or award · Stock Option (right to buy) +20,724 20,724
2022-05-12 Spigelman Melvin K Director Grant or award · Stock Option (right to buy) +10,362 10,362
2022-05-12 Krause Kevin Michael Chief Strategy Officer Grant or award · Stock Option (right to buy) +66,000 66,000
2022-05-12 Day Lucy Chief Financial Officer Grant or award · Stock Option (right to buy) +66,000 66,000
2022-05-12 Zakrzewski Joseph S Director Grant or award · Stock Option (right to buy) +10,362 10,362
2022-05-12 Marks Gilbert Lynn Director Grant or award · Stock Option (right to buy) +10,362 10,362
2022-05-12 Easom Eric Chief Executive Officer Grant or award · Stock Option (right to buy) +225,000 225,000
2022-05-05 FitzPatrick Margaret M Director Grant or award · Stock Option (right to buy) +11,463 11,463
2022-03-29 Adjuvant Global Health Technology Fund, L.P. 10% owner Conversion +1,651,636 1,651,636
2022-03-29 Adjuvant Global Health Technology Fund, L.P. 10% owner Conversion +312,415 312,415

Page 17 of 20 · 385 trades